🔴 Inovio Pharmaceuticals is trading 13.22% down with no direct catalyst identified

Inovio Pharmaceuticals is trading 13.22% lower at $0.81 amid weaker markets; no October 29 company announcement explaining the drop was identified.

• The latest major company news remains the October 20 court judgment, whose collectability the company cautioned could be impaired.
• The Nasdaq Composite was down 1.47% in the supplied market context.
• The FDA’s October 30 target decision date for INO-3107 is approaching, but available sources do not establish it as the direct cause of this intraday move.